Common treatments for non-Hodgkin’s B-cell lymphoma infiltrating bone marrow include chemotherapy, radiation therapy, biotargeted therapy and so on. 1. Chemotherapy: chemotherapeutic drugs are mainly used to inhibit the tumor by stopping the growth of cancer cells. It is mainly CHOP regimen plus rituximab. CHOP regimen is cyclophosphamide, adriamycin, vincristine, prednisone. Patients in chemotherapy and after chemotherapy appear protein consumption increases, the body shows negative nitrogen, then should supply sufficient protein, maintain the nitrogen balance of the body. 2. Radiotherapy: radiotherapy generally utilizes X-rays, electrons and protons to destroy cancer cells. Radiotherapy is usually used in conjunction with chemotherapy, which is usually used in the treatment of limited lymphoma. 3. Biological targeted therapy: Rituximab and radioimmunotherapy are commonly used. Rituximab binds to antigens on the cell surface, thus activating B-cell death. Radioimmunotherapy is to label antibodies with radionuclides that have cytotoxic effects, and use the guiding effect of the antibodies to make the radionuclides reach the target sites and kill the tumor cells. Non-Hodgkin’s B-cell lymphoma infiltrating bone marrow is often selected as a combination of chemotherapy and local radiotherapy to the primary foci. Through comprehensive treatment, the development of the disease can be effectively controlled, the rate of recurrence and metastasis can be reduced, and the survival time of the patients can be prolonged. When non-Hodgkin’s B-cell lymphoma infiltrating bone marrow is diagnosed, the medication and treatment should be standardized according to the doctor’s prescription.